Insights: Publications Elutia Founder and CEO Offers Insight on Kilpatrick Townsend's Impactful Guidance
Elutia Founder and CEO C. Randal Mills, Ph.D. says, “In September, our company accomplished three key milestones:
1) We rebranded as Elutia to reflect our strategic focus on drug eluting biomatrix technology,
2) sold our Orthobiologics Business Unit, and
3) closed a private placement for proceeds up to $26M.
Each of these major corporate events would not have been possible without the help from the dedicated team at Kilpatrick Townsend & Stockton LLP.
Led by Michael "Mick" Cochran, David M. Eaton, Agnes Trenche Mora, Catherine Zhu, and Paige Clifton, we received the highest level of legal support and counsel to help guide us through each of these complex announcements. I am personally appreciative of Kilpatrick’s unparalleled commitment and professionalism. We look towards continuing our relationship as our company executes on future milestones.”
Related People View All
While we are pleased to have you contact us by telephone, surface mail, electronic mail, or by facsimile transmission, contacting Kilpatrick Townsend & Stockton LLP or any of its attorneys does not create an attorney-client relationship. The formation of an attorney-client relationship requires consideration of multiple factors, including possible conflicts of interest. An attorney-client relationship is formed only when both you and the Firm have agreed to proceed with a defined engagement.
DO NOT CONVEY TO US ANY INFORMATION YOU REGARD AS CONFIDENTIAL UNTIL A FORMAL CLIENT-ATTORNEY RELATIONSHIP HAS BEEN ESTABLISHED.
If you do convey information, you recognize that we may review and disclose the information, and you agree that even if you regard the information as highly confidential and even if it is transmitted in a good faith effort to retain us, such a review does not preclude us from representing another client directly adverse to you, even in a matter where that information could be used against you.